TrialCancer research communications2022

Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade-resistant Melanoma for Anti-PD-L1 Rechallenge.

Andre van der Westhuizen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.